Matinas BioPharma Holdings Inc (MTNB) Set to Announce Quarterly Earnings on Monday
Matinas BioPharma Holdings Inc (NASDAQ:MTNB) is scheduled to be issuing its quarterly earnings data on Monday, November 13th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter.
Matinas BioPharma Holdings (NASDAQ:MTNB) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.02 million. Matinas BioPharma Holdings had a negative net margin of 8,834.65% and a negative return on equity of 143.22%.
Matinas BioPharma Holdings Inc (NASDAQ:MTNB) opened at $1.10 on Monday. Matinas BioPharma Holdings Inc has a 1-year low of $1.01 and a 1-year high of $3.99.
In related news, Director Adam K. Stern purchased 100,000 shares of Matinas BioPharma Holdings stock in a transaction dated Friday, September 8th. The stock was bought at an average price of $1.38 per share, for a total transaction of $138,000.00. Following the completion of the acquisition, the director now directly owns 793,992 shares of the company’s stock, valued at $1,095,708.96. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders bought 110,000 shares of company stock valued at $151,250 in the last quarter.
A hedge fund recently bought a new stake in Matinas BioPharma Holdings stock. California State Teachers Retirement System purchased a new position in shares of Matinas BioPharma Holdings Inc (NASDAQ:MTNB) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 93,500 shares of the company’s stock, valued at approximately $158,000. California State Teachers Retirement System owned approximately 0.10% of Matinas BioPharma Holdings at the end of the most recent quarter.
MTNB has been the subject of several research analyst reports. Maxim Group set a $6.00 price target on shares of Matinas BioPharma Holdings and gave the company a “buy” rating in a report on Tuesday, August 8th. Roth Capital set a $9.00 price target on shares of Matinas BioPharma Holdings and gave the company a “buy” rating in a report on Thursday, August 10th.
About Matinas BioPharma Holdings
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.
Receive News & Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.